Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04062032 · ClinicalTrials.gov registry record · Phase 2

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

A Phase 2 study of Melanoma (Skin), sponsored by University of Utah.

Completed
Registry status
Phase 2
Development phase
41
Enrollment target
1
Study location

NCT04062032: Completed Phase 2 study of Melanoma (Skin), sponsored by University of Utah.

NCT04062032 is a Phase 2 study of Melanoma (Skin) that has completed, run by University of Utah. The registered enrollment target is 41 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04062032, a Phase 2 study of Melanoma (Skin), has completed, sponsored by University of Utah.

COMPLETED
Registry status
Phase 2
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.

Primary Outcome

Concentration (ng/mL) of pre-treatment ASA metabolites (salicylate and salicylurate) in plasma will be compared to the concentration of ASA metabolites at day 7

Conditions Studied

Melanoma (Skin)

Interventions

  • DRUG Aspirin 325mg
  • DRUG Aspirin 81 mg

Study Locations (1)

Utah

  • Huntsman Cancer Institute/University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2016-09-27
Est. Completion 2019-02-27
Phase Phase 2
University of Utah

818 total trials

What the finished NCT04062032 record still lists

NCT04062032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which Aspirin 325mg is the first listed.

NCT04062032 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT04062032 about?

NCT04062032 is a clinical study titled "Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma". This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.

What is the current status of trial NCT04062032?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2016-09-27. Estimated completion is 2019-02-27.

What conditions does trial NCT04062032 study?

This clinical trial studies the following conditions: Melanoma (Skin).

What interventions are being tested in trial NCT04062032?

The interventions under investigation include: Aspirin 325mg (DRUG), Aspirin 81 mg (DRUG).

Who is sponsoring clinical trial NCT04062032?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04062032 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma (Skin)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04062032's enrollment target sits among peer trials

41 12th of 30 higher than 19 of 30 other Melanoma (Skin) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04062032, the US trial registry maintained by the National Library of Medicine. NCT04062032 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.